Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics' stock price has experienced significant fluctuations. On November 25, 2025, the share price was $4.60, a 75.87% decrease from $19.06 on November 26, 2024. Recent events include Martin Shkreli identifying the company as a short target, the presentation of new data on loading therapeutic oligonucleotides into exosomes, the report of Third Quarter 2025 Financial Results, the publication of a peer-reviewed study on Deramiocel's mechanism of action, an investigation into potential wrongdoing by officers and directors, the FDA's refusal to approve Deramiocel, diverse analyst outlooks, and the announcement of financial results for the first quarter ended March 31, 2024.

Information detailing the demand seasonality for Capricor Therapeutics' products is not readily available. Demand for its products would likely be driven by medical need rather than traditional seasonal consumer patterns. The company's stock price can exhibit seasonality.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for muscular and other diseases with unmet medical needs. Their lead product candidate, Deramiocel (CAP-1002), is in Phase 3 clinical trials for Duchenne muscular dystrophy (DMD). The company is also developing an exosome technology platform, including an Exosome protein-based vaccine in preclinical trials for SARS-CoV-2, the StealthX Exosome Platform for vaccine and therapeutic development, and CAP-2003 for DMD.

Capricor Therapeutics is headquartered in San Diego, California, and focuses on developing therapeutics for diseases with unmet medical needs in the United States. They have a partnership with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of CAP-1002 for DMD in the United States and Japan.

Capricor Therapeutics' brand reputation has been impacted by clinical trial developments and public commentary. The FDA's refusal to approve Deramiocel and Martin Shkreli's negative comments affected the company's reputation. However, data presentations at scientific meetings, peer-reviewed studies, and the full enrollment of Cohort A in the Phase 3 HOPE-3 trial are positive developments.

Capricor Therapeutics has a diverse ownership structure. Individual investors hold approximately 47% of the company, institutional shareholders hold about 31.56%, and insiders own 85.18%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, VTSMX, Susquehanna International Group, Llp, IWM, Geode Capital Management, Llc, State Street Corp, and Citadel Advisors Llc. Nippon Shinyaku Co., Ltd. owns 7.09 million shares, representing 15.51% of the company.